Hunter-Hopkins Center

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Hunter-Hopkins Center is a clinic in Charlotte, North Carolina, United States that specializes in treating patients with fibromyalgia, ME/CFS, and related conditions, and takes part in research into ME/CFS.[1][2][3] After the retirement of founder Dr Charles Lapp, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman.[4]

Ampligen[edit | edit source]

The Hunter-Hopkins Center, along with Nevada's Sierra Internal Medicine are the two primary clinics conducting clinical trials into Ampligen (rintatolimod) for severe and very severe ME, and for Long COVID patients meeting CFS criteria.[1][2]
Ampligen is an unlicensed drug available to some patients under the compassionate use program.[2]

MCAM[edit | edit source]

Hunter-Hopkins Center has also taken part in the CDC's Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome or MCAM.[1][5]

Charles Lapp[edit | edit source]

Dr Charles Lapp, founder of the Hunter-Hopkins Center, specialized in ME/CFS and was medical director at the Hunter-Hopkins Center until retiring in 2018.[3][6][4][7] Dr Lapp has helped run a number of clinicial trials for Ampligen in CFS patients.[8]

Laura Black[edit | edit source]

Dr Laura Black continued on staff since Dr Lapp's retirement but retired in 2019.[4][9]

Vincent Hillman[edit | edit source]

Dr Vincent F. Hillman took over as medical director in 2018, and has a family member with chronic fatigue syndrome.[4][9][10]

Interviews, talks and news articles[edit | edit source]

Notable studies and research[edit | edit source]

Articles for patients[edit | edit source]

Online prescence[edit | edit source]

Hunter-Hopkins Center, PLLC
7421 Carmel Executive Park Dr.
North Carolina
United States, 288226
  • Phone (704)543-9692
  • Facsimile: (704)543-8547
  • Email:

See also[edit | edit source]

Learn more[edit | edit source]

  • Research - Hunter Hopkins Center - Dr Lapp

References[edit | edit source]

  1. "Research | Hunter-Hopkins Center, PLLC". Retrieved April 13, 2022.
  2. "Ampligen in Chronic Fatigue Syndrome". Retrieved August 13, 2018.
  3. 3.03.1 "Hunter-Hopkins Center, PLLC | specializing in fibromyalgia, chronic fatigue syndrome, and related conditions". Retrieved April 13, 2022.
  4. Lapp, Charles (February 12, 2018). "Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm". Hunter-Hopkins Center. Retrieved December 23, 2018.
  5. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017). "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study". American Journal of Epidemiology. 1–10. doi:10.1093/aje/kwx029.
  6. "Contact | Hunter-Hopkins Center, PLLC". Retrieved April 13, 2022.
  7. Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012). "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome". PLoS One. 7 (3): e31334. doi:10.1371/journal.pone.0031334. PMID 22431963.
  8. "History of Changes for Study: NCT00215813 | Study of Ampligen in Chronic Fatigue Syndrome". April 8, 2010. Retrieved April 13, 2020.
  9. 9.09.1 "Dr. Black Retires". Hunter-Hopkins Center. October 6, 2019. Retrieved April 13, 2020.
  10. "Staff | Vincent F. Hillman, M". Hunter-Hopkins Center. Retrieved April 14, 2022.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more:

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.